HARROW INC (HROW) Stock Fundamental Analysis
NASDAQ:HROW - Nasdaq - US4158581094 - Common Stock - Currency: USD
Taking everything into account, HROW scores 4 out of 10 in our fundamental rating. HROW was compared to 194 industry peers in the Pharmaceuticals industry. HROW may be in some trouble as it scores bad on both profitability and health. HROW is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
HROW had negative earnings in the past year.
HROW had a positive operating cash flow in the past year.
HROW had negative earnings in 4 of the past 5 years.
Of the past 5 years HROW 4 years had a positive operating cash flow.
1.2 Ratios
HROW has a Return On Assets of -9.50%. This is in the better half of the industry: HROW outperforms 70.81% of its industry peers.
HROW's Return On Equity of -57.62% is in line compared to the rest of the industry. HROW outperforms 53.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.5% | ||
| ROE | -57.62% | ||
| ROIC | N/A |
ROA(3y)-11.86%
ROA(5y)-8.23%
ROE(3y)-83.03%
ROE(5y)-52.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HROW's Operating Margin has declined in the last couple of years.
HROW has a better Gross Margin (72.56%) than 78.38% of its industry peers.
HROW's Gross Margin has improved in the last couple of years.
HROW does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.56% |
OM growth 3Y-25.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y2.98%
2. Health
2.1 Basic Checks
HROW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HROW has more shares outstanding
HROW has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HROW has an improved debt to assets ratio.
2.2 Solvency
HROW has an Altman-Z score of 2.06. This is not the best score and indicates that HROW is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of HROW (2.06) is better than 68.11% of its industry peers.
The Debt to FCF ratio of HROW is 60.96, which is on the high side as it means it would take HROW, 60.96 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 60.96, HROW is in the better half of the industry, outperforming 75.14% of the companies in the same industry.
A Debt/Equity ratio of 3.21 is on the high side and indicates that HROW has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.21, HROW is doing worse than 84.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.21 | ||
| Debt/FCF | 60.96 | ||
| Altman-Z | 2.06 |
ROIC/WACCN/A
WACC10.36%
2.3 Liquidity
A Current Ratio of 1.55 indicates that HROW should not have too much problems paying its short term obligations.
HROW has a worse Current ratio (1.55) than 71.35% of its industry peers.
HROW has a Quick Ratio of 1.44. This is a normal value and indicates that HROW is financially healthy and should not expect problems in meeting its short term obligations.
HROW has a Quick ratio of 1.44. This is in the lower half of the industry: HROW underperforms 65.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for HROW have decreased strongly by -106.67% in the last year.
Looking at the last year, HROW shows a very strong growth in Revenue. The Revenue has grown by 48.15%.
The Revenue has been growing by 25.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)48.15%
Revenue growth 3Y38.63%
Revenue growth 5Y25.77%
Sales Q2Q%43.75%
3.2 Future
The Earnings Per Share is expected to grow by 74.53% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 52.09% on average over the next years. This is a very strong growth
EPS Next Y5.42%
EPS Next 2Y59.21%
EPS Next 3Y67.86%
EPS Next 5Y74.53%
Revenue Next Year45.18%
Revenue Next 2Y46.13%
Revenue Next 3Y44.62%
Revenue Next 5Y52.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HROW. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 73.15, the valuation of HROW can be described as expensive.
Based on the Price/Forward Earnings ratio, HROW is valued a bit cheaper than the industry average as 73.51% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HROW to the average of the S&P500 Index (22.68), we can say HROW is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 73.15 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 74.59% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 75.68% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 337.78 | ||
| EV/EBITDA | 283.54 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HROW does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as HROW's earnings are expected to grow with 67.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.21%
EPS Next 3Y67.86%
5. Dividend
5.1 Amount
No dividends for HROW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
28.95
-1.18 (-3.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners59.06%
Inst Owner Change-96.25%
Ins Owners13.21%
Ins Owner Change1.08%
Market Cap1.03B
Analysts84
Price Target59.04 (103.94%)
Short Float %9.66%
Short Ratio8.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.71%
Min EPS beat(2)-127.34%
Max EPS beat(2)13.92%
EPS beat(4)1
Avg EPS beat(4)-162.09%
Min EPS beat(4)-448.69%
Max EPS beat(4)13.92%
EPS beat(8)2
Avg EPS beat(8)-190.39%
EPS beat(12)3
Avg EPS beat(12)-1204.53%
EPS beat(16)5
Avg EPS beat(16)-976.5%
Revenue beat(2)1
Avg Revenue beat(2)2.16%
Min Revenue beat(2)-8.55%
Max Revenue beat(2)12.87%
Revenue beat(4)1
Avg Revenue beat(4)-2.04%
Min Revenue beat(4)-8.55%
Max Revenue beat(4)12.87%
Revenue beat(8)3
Avg Revenue beat(8)-2.27%
Revenue beat(12)6
Avg Revenue beat(12)-0.36%
Revenue beat(16)9
Avg Revenue beat(16)1.32%
PT rev (1m)-3.29%
PT rev (3m)-4.88%
EPS NQ rev (1m)-104.21%
EPS NQ rev (3m)-103.55%
EPS NY rev (1m)-4.33%
EPS NY rev (3m)-64.36%
Revenue NQ rev (1m)-9.51%
Revenue NQ rev (3m)-9.51%
Revenue NY rev (1m)-0.35%
Revenue NY rev (3m)-5.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 73.15 | ||
| P/S | 6.1 | ||
| P/FCF | 337.78 | ||
| P/OCF | 241.04 | ||
| P/B | 17.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 283.54 |
EPS(TTM)-0.93
EYN/A
EPS(NY)0.4
Fwd EY1.37%
FCF(TTM)0.09
FCFY0.3%
OCF(TTM)0.12
OCFY0.41%
SpS4.75
BVpS1.63
TBVpS-3.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.5% | ||
| ROE | -57.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.56% | ||
| FCFM | 1.8% |
ROA(3y)-11.86%
ROA(5y)-8.23%
ROE(3y)-83.03%
ROE(5y)-52.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.27%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-25.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y2.98%
F-Score6
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.21 | ||
| Debt/FCF | 60.96 | ||
| Debt/EBITDA | 46.1 | ||
| Cap/Depr | 9.72% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 105.97% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 2.06 |
F-Score6
WACC10.36%
ROIC/WACCN/A
Cap/Depr(3y)472.09%
Cap/Depr(5y)305.32%
Cap/Sales(3y)40.85%
Cap/Sales(5y)25.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y5.42%
EPS Next 2Y59.21%
EPS Next 3Y67.86%
EPS Next 5Y74.53%
Revenue 1Y (TTM)48.15%
Revenue growth 3Y38.63%
Revenue growth 5Y25.77%
Sales Q2Q%43.75%
Revenue Next Year45.18%
Revenue Next 2Y46.13%
Revenue Next 3Y44.62%
Revenue Next 5Y52.09%
EBIT growth 1Y-343.52%
EBIT growth 3Y2.64%
EBIT growth 5YN/A
EBIT Next Year248.81%
EBIT Next 3Y150.03%
EBIT Next 5Y140.5%
FCF growth 1Y47.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.83%
OCF growth 3YN/A
OCF growth 5Y40.96%